Click image to enlarge
IPO or bust for emerging medtechs
oculartherapeutix
Smith & Nephew plans to reveal new strategy for mature markets | Medtech Wall Street news for the week of July 28, 2014
Ocular Therapeutix prices IPO below range
Ocular Therapeutix said this morning that it plans to put up 5 million shares at $13 apiece on the NASDAQ exchange today.
That’s a dollar below the projected price range the Bedford, Mass.-based company issued earlier this month.
Ocular Therapeutix looks to raise $80M in IPO | Medtech Wall Street news for the week of July 14, 2014
Ocular Therapeutix sets terms for IPO
Ocular Therapeutix is looking to raise as much as $80 million in a forthcoming initial public offering, the company said today.
Bedford, Mass.-based Ocular Therapeutix said it plans to offer 5 million shares at $14 to $16 apiece, making the IPO worth $70 million to $80 million.
Ocular Therapeutix launches Phase III trial for eye plug
Bedford, mass.-based Ocular Therapeutix launched Phase III human clinical studies of its drug-releasing optical plug in patients undergoing cataract surgery.
Ocular Therapeutix lands reimbursement code for eye plugs
Ocular Therapeutix said it landed a reimbursement code for the insertion of the drug-eluting eye plugs it’s developing to treat glaucoma.
Bedford, mass.-based Ocular Therapeutix said the American Medical Assn. issued a CPT code "for the insertion of a drug-eluting implant, including punctal dilation and implant removal when performed, into the lacrimal canaliculus."
Ocular Therapeutix lands FDA approval for ReSure sealant
Massachusetts medical device maker Ocular Therapeutix announced today that it won FDA premarket approval for its flagship ReSure sealant, a hydrogel designed to help heal surgical wounds in the eye.
Study: Ocular Therapeutix touts Phase II results for sustained-release eye therapy implant
Ocular Therapeutix, the latest endeavor of serial entrepreneur Amar Sawhney, released positive findings from a Phase II study of its absorbable intracanalicular plug, designed to provide long-term drug therapy following eye surgery.
UPDATE: FDA panel approves Ocular Therapeutix’ ReSeal, with reservations
An FDA advisory panel voted yesterday that Ocular Therapeutix’s ReSure topical hydrogel post-op sealant is safe, but split on questions of efficacy and whether the benefits of the treatment outweigh its risks.
The FDA’s Ophthalmic Devices Panel voted 9-1, with 1 abstention, that the ReSure sealant is safe; 5-3, with 3 abstentions, that it is effective; and 5-1, with 5 abstentions, that its benefits outweigh its risks.
FDA eye experts give mixed recommendation for post-op sealant
A panel of experts today voted that Ocular Therapeutix’s ReSure Sealant topical hydrogel post-op sealant is safe, but panelists were split on questions of efficacy and whether the benefits of the treatment outweigh the risks.
